Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Van Beveren, N J M ^a,b   Schwarz, E ^c   Noll, R ^d   Guest, P C ^c   Meijer, C ^e   De Haan, L ^e   Bahn, S ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Delta Center for Mental Health Care   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d DESALES UNIVERSITY   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; CARCINOEMBRYONIC ANTIGEN; CD5L ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH HORMONE; IMMUNOGLOBULIN M; INSULIN; PEPTIDES AND PROTEINS; PROINSULIN; T LYMPHOCYTE SECRETED PROTEIN I 309; UNCLASSIFIED DRUG; CD5 ANTIGEN; CHROMOGRANIN A; GAMMA INTERFERON; HAPTOGLOBIN; HYDROCORTISONE; INTERFERON GAMMA INDUCED PROTEIN 10; PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOPHENOTYPE; FEMALE; HUMAN; IMMUNOASSAY; INFLAMMATION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCHIZOPHRENIA; SIBLING; BODY MASS; MOOD DISORDER; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; SIGNAL TRANSDUCTION;

EID: 84907352334     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.52     Document Type: Article

References (42)

1. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2004; 160: 284-289.
2. Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, Shyu KG et al. Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005; 133B: 1-5.
3. Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M et al. Increased alpha- defensins as a blood marker for schizophrenia susceptibility. Mol Cell Proteomics 2007; 7: 1204-1213.
4. Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: e9166.
5. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010; 15: 118-119.
6. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S et al. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2010; 15: 1088-1100.
7. Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L et al. Identification of targeted analyte clusters for studies of schizophrenia. Mol Cell Proteomics. 2010; 9: 510-522.
8. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011; 36: 1092-1096.
9. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494-502.
10. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012; 46: 819-824.
11. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology 2012; 37: 1901-1911.
12. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K et al. Potential metabolite markers of schizophrenia. Mol Psychiatry 2013; 18: 67-78.
13. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008; 93: 572-577.
14. Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004; 65: 1335-1342.
15. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-697.
16. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S et al. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 2010; 44: 1176-1189.
17. English JA, Pennington K, Dunn MJ, Cotter DR. The neuroproteomics of schizophrenia. Biol Psychiatry 2011; 69: 163-172.
18. Tsuang MT, Faraone SV, Lyons MJ. Identification of the phenotype in psychiatric genetics. Eur Arch Psychiatry Clin Neurosci 1993; 243: 131-142.
19. Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999; 56: 162-168.
20. McGue M, Gottesman II. The genetic epidemiology of schizophrenia and the design of linkage studies. Eur Arch Psychiatry Clin Neurosci 1991; 240: 174-181.
21. Olin SC, Mednick SA. Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull 1996; 22: 223-240.
22. Rouillon F, Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur Psychiatry 20054: S345-S348.
23. Korver N, Quee PJ, Boos HB, Simons CJ, de Haan L. GROUP investigators: Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res 2012; 21: 205-221.
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
25. Stefanis NC, Hanssen M, Smirnis NK, Avramopoulos DA, Evdokimidis IK, Stefanis CN et al. Evidence that three dimensions of psychosis have a distribution in the general population. Psychol Med 2002; 32: 347-358.
26. Hutton JC. Insulin secretory granule biogenesis and the proinsulin-processing endopeptidases. Diabetologia 1994; 37: S48-S56.
27. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006; 3: e327.
28. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102-1117.
29. Brown GG, Thompson WK. Functional brain imaging in schizophrenia: selected results and methods. Curr Top Behav Neurosci 2010; 4: 181-214.
30. Dominici FP, Turyn D. Growth hormone-induced alterations in the insulinsignaling system. Exp Biol Med (Maywood) 2002; 227: 149-157.
31. Murray R, Shalet S. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency. Clin Endocrinol (Oxford) 2005; 62: 182-188, 2005.
32. Arafat AM, Möhlig M, Weickert MO, Schöfl C, Spranger J, Pfeiffer AF et al. Improved insulin sensitivity, preserved beta cell function and improved wholebody glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study. Diabetologia 2010; 53: 1304-1313.
33. Kahn RS, Davidson M, Hirschowitz J, Stern RG, Davis BM, Gabriel S et al. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects. Psychiatry Res 1992; 41: 155-161.
34. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995; 15: 4 S-10 S.
35. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010; 21: 261-267.
36. Harris LW, Guest PC, Wayland MT, Umrania Y, Krishnamurthy D, Rahmoune H et al. Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology 2012; 38: 752-766.
37. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007; 12: 934-945.
38. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010; 15: 938-953.
39. Yao JK, Condray R, Dougherty GG Jr, Keshavan MS, Montrose DM, Matson WR et al. Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS One 2012; 7: e42165.
40. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 2010; 5: e9508.
41. Condray R, Dougherty GG Jr, Keshavan MS, Reddy RD, Haas GL, Montrose DM et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neurolepticnaive patients with schizophrenia. Int J Neuropsychopharmacol 2011; 14: 756-767.
42. Yao JK, Dougherty GG, Reddy RD, Matson WR, Kaddurah-Daouk R, Keshavan MS. et al. Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis. Front Cell Neurosci 2013; 7: 90.